Skip to main content
Equibles
PBLS logo

PBLS · Parabilis Medicines, Inc. · Metrics

Track PBLS — free

Use PBLS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PBLS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$29.79 +0.54 (+1.85%)
Russell 2000 member Rebalance outlook locked
Market Cap
$3.70B
Shares
123.53M
Volume · Nov 4 501.62K Avg daily vol (3M) 887.95K

PBLS metrics

35 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$29.25
Market cap
$3.70B

Price action

20 metrics
Price change (1W)
+10.3%
Price change (30D)
-0.9%
Price change (3M)
-18.5%
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
74.9%
Annualized volatility (3M)
74.7%
Beta
0.5
RSI (14D)
51.6
Price vs SMA 50
-10.1%
Price vs SMA 200
—
Avg volume (3M)
887,953
Relative volume
0.6
Average dollar volume
$29.30M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
123.53M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
3.5
reciprocal yield 28.3%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
—
Net income (TTM)
—
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$8.59

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+1,331.7%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
—
Debt / equity
0.0
Current ratio
17.9
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
17.9
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$1.11B
Latest balance sheet
Cash & equivalents
$1.09B
Total assets
$1.18B
Total debt
$6.41M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
—
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
79
13F filer change QoQ
+79
Institutional ownership
80.1%
Conviction holders (share of 13F filers)
13.9%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
1.0
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
2.0%

Short interest

3 metrics
Short interest
7.5%
Latest settlement · 9.5 days to cover
Days to cover
9.5d
Short-squeeze score
75 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1657677 CUSIP 698955101 13F (30d) 17 filings 17 filers Visit website Investor relations